Volume 21, Issue 4 (Winter 2024)
Sci J Iran Blood Transfus Organ 2024, 21(4): 333-345 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Kheiriardahaei F, Yari F. Effective factors in creating immunization against a desired antigen in the culture medium. Sci J Iran Blood Transfus Organ 2024; 21 (4) :333-345
URL: http://bloodjournal.ir/article-1-1562-en.html
URL: http://bloodjournal.ir/article-1-1562-en.html
Abstract: (325 Views)
Abstract
Background and Objectives
Antibodies are glycoprotein molecules that play a significant role in both diagnosis and treatment. Various methods exist for their production, with laboratory immunization being one of them. This study aims to investigate the laboratory immunization method and the factors influencing the optimization of immunization to achieve antibody-producing immunized lymphocytes in a laboratory setting.
Materials and Methods
A literature review was conducted using the databases in PubMed and Google Scholar, employing the keywords immunization, in vitro technique, and antibodies, covering the period from 1985 to 2023. About 50 articles were found with these keywords, 34 of which are used in this article.
Results
The studies reviewed indicate that in vitro immunization offers several advantages over in vivo immunization, including shorter immunization time, high reproducibility, and the ability to obtain IgM-producing clones. However, this method is not universally applicable for producing antibodies against all antigens. Numerous factors influence laboratory immunization, including the type and concentration of the antigen, the type and number of lymphocytes, the removal of immune-suppressing cells, the use of adjuvants and cytokines, the physiological conditions of the culture environment, the incubation duration, and the variability in immune responses among donors.
Conclusions
For the production of antibodies in vitro, it is essential to consider the effective factors to enhance the efficiency of laboratory immunization.
Background and Objectives
Antibodies are glycoprotein molecules that play a significant role in both diagnosis and treatment. Various methods exist for their production, with laboratory immunization being one of them. This study aims to investigate the laboratory immunization method and the factors influencing the optimization of immunization to achieve antibody-producing immunized lymphocytes in a laboratory setting.
Materials and Methods
A literature review was conducted using the databases in PubMed and Google Scholar, employing the keywords immunization, in vitro technique, and antibodies, covering the period from 1985 to 2023. About 50 articles were found with these keywords, 34 of which are used in this article.
Results
The studies reviewed indicate that in vitro immunization offers several advantages over in vivo immunization, including shorter immunization time, high reproducibility, and the ability to obtain IgM-producing clones. However, this method is not universally applicable for producing antibodies against all antigens. Numerous factors influence laboratory immunization, including the type and concentration of the antigen, the type and number of lymphocytes, the removal of immune-suppressing cells, the use of adjuvants and cytokines, the physiological conditions of the culture environment, the incubation duration, and the variability in immune responses among donors.
Conclusions
For the production of antibodies in vitro, it is essential to consider the effective factors to enhance the efficiency of laboratory immunization.
References
1. Liu JK. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg (Lond) 2014; 3(4): 113-6. [DOI:10.1016/j.amsu.2014.09.001] [PMID] []
2. Voak D. Monoclonal antibodies as blood grouping reagents. Baillieres Clin Haematol 1990; 3(2): 219-42. [DOI:10.1016/S0950-3536(05)80048-4] [PMID]
3. Trier NH, Houen G. Peptide Antibodies in Clinical Laboratory Diagnostics. Adv Clin Chem 2017; 81: 43-96. [DOI:10.1016/bs.acc.2017.01.002] [PMID]
4. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9(10): 767-74. [DOI:10.1038/nrd3229] [PMID]
5. Panch SR, Montemayor-Garcia C, Klein HG. Hemolytic Transfusion Reactions. N Engl J Med 2019; 381(2): 150-62. [DOI:10.1056/NEJMra1802338] [PMID]
6. Matsumoto SE, Yamashita M, Katakura Y, Aiba Y, Tomimatsu K, Kabayama S, et al. A rapid and efficient strategy to generate antigen-specific human monoclonal antibody by in vitro immunization and the phage display method. J Immunol Methods 2008; 332(1-2): 2-9. [DOI:10.1016/j.jim.2007.12.005] [PMID]
7. Xu H, Xiang X, Ding W, Dong W, Hu Y. The Research Progress on Immortalization of Human B Cells. Microorganisms 2023; 11(12): 2936. [DOI:10.3390/microorganisms11122936] [PMID] []
8. Borrebaeck CA, Danielsson L, Möller SA. Human monoclonal antibodies produced from L-leucine methyl ester-treated and in vitro immunized peripheral blood lymphocytes. Biochem Biophys Res Commun 1987; 148(3): 941-6. [DOI:10.1016/S0006-291X(87)80223-1] [PMID]
9. Borrebaeck CA. Development of in vitro immunization in murine and human hybridoma technology. J Pharm Biomed Anal 1987; 5(8): 783-92. [DOI:10.1016/0731-7085(87)80096-1] [PMID]
10. Kato M, Yan H, Tsuji NM, Chiba T, Hanyu Y. A method for inducing antigen-specific IgG production by in vitro immunization. J Immunol Methods 2012; 386(1-2): 60-9. [DOI:10.1016/j.jim.2012.08.019] [PMID]
11. Borrebaeck CA, Danielsson L, Möller SA. Human monoclonal antibodies produced by primary in vitro immunization of peripheral blood lymphocytes. Proc Natl Acad Sci U S A 1988; 85(11): 3995-9. [DOI:10.1073/pnas.85.11.3995] [PMID] []
12. Thiele DL, Lipsky PE. Mechanism of L-leucyl-L-leucine methyl ester-mediated killing of cytotoxic lymphocytes: dependence on a lysosomal thiol protease, dipeptidyl peptidase I, that is enriched in these cells. Proc Natl Acad Sci U S A 1990; 87(1): 83-7. [DOI:10.1073/pnas.87.1.83] [PMID] []
13. Tobeyani F, Milani S, Yari F. Evaluation of effective factors during an in Vitro immunization against Kell blood group antigen. Sci J Iran Blood Transfus Organ 2022; 19(2):108-21. [Article in Farsi]
14. Lagacé J, Brodeur BR. Parameters affecting in vitro immunization of human lymphocytes. J Immunol Methods 1985; 85(1): 127-36. [DOI:10.1016/0022-1759(85)90281-9] [PMID]
15. Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol 2013; 4: 114. [DOI:10.3389/fimmu.2013.00114] [PMID] []
16. Jiang W, Lederman MM, Harding CV, Rodriguez B, Mohner RJ, Sieg SF. TLR9 stimulation drives naïve B cells to proliferate and to attain enhanced antigen presenting function. Eur J Immunol 2007; 37(8): 2205-13. [DOI:10.1002/eji.200636984] [PMID]
17. Matsuda Y, Imamura R, Takahara S. Evaluation of Antigen-Specific IgM and IgG Production during an In Vitro Peripheral Blood Mononuclear Cell Culture Assay. Front Immunol 2017; 8: 794. [DOI:10.3389/fimmu.2017.00794] [PMID] []
18. Liu W, Tolar P, Song W, Kim TJ. Editorial: BCR Signaling and B Cell Activation. Front Immunol 2020; 11: 45. [DOI:10.3389/fimmu.2020.00045] [PMID] []
19. Xu TT, Qi Y, Pan Y, Li SQ, Chen HX, Li JM, et al. Screening of immune adjuvant and optimization of immunization protocol of glycoprotein D2 subunit vaccine against herpes simplex virus type 2. Chinese Journal of Biologicals 2018; 31: 689-94.
20. Zhang B, Yuan C, Song X, Xu L, Yan R, Shah MAA, et al. Optimization of Immunization Procedure for Eimeria tenella DNA Vaccine pVAX1-pEtK2-IL-2 and Its Stability. Acta Parasitol 2019; 64(4): 745-52. [DOI:10.2478/s11686-019-00090-4] [PMID]
21. Amrovani M, Yari F, Milani S, Amoohossein B. Evaluation of effective factors in the optimization of immunization to achieve antibodies against RhD antigen in culture medium. Sci J Iran Blood Transfus Organ 2022; 19(4): 257-69.
22. Pissas G, Eleftheriadis T. Assessment of Humoral Alloimmunity in Mixed Lymphocyte Reaction. Bio Protoc 2019; 9(2): e3139. [DOI:10.21769/BioProtoc.3139] [PMID] []
23. Milani S, Yari F. Alloimmune lymphocytes proliferation in presence of Mixed Lymphocyte Culture and cyclosporine. Sci J Iran Blood Transfus Organ 2021; 18(2): 97-104. [Article in Farsi]
24. Ichikawa A, Katakura Y, Teruya K, Hashizume S, Shirahata S. In vitro immunization of human peripheral blood lymphocytes: establishment of B cell lines secreting IgM specific for cholera toxin B subunit from lymphocytes stimulated with IL-2 and IL-4. Cytotechnology 1999; 31(1-2): 133-41.
25. Xu Q, Katakura Y, Yamashita M, Fang S, Tamura T, Matsumoto SE, et al. IL-10 augments antibody production in in vitro immunized lymphocytes by inducing a Th2-type response and B cell maturation. Biosci Biotechnol Biochem 2004; 68(11): 2279-84. [DOI:10.1271/bbb.68.2279] [PMID]
26. Yamashita M, Katakura Y, Aiba Y, Matsumoto SE, Morihara K, Teruya K, et al. Involvement of IL-10 in the suppression of antibody production by in vitro immunized peripheral blood mononuclear cells. Cytotechnology 2007; 55(2-3): 71-7. [DOI:10.1007/s10616-007-9088-x] [PMID] []
27. Danielsson L, Möller SA, Borrebaeck CA. Effect of cytokines on specific in vitro immunization of human peripheral B lymphocytes against T-cell dependent antigens. Immunology 1987; 61(1): 51-5.
28. Sprenger KG, Louveau JE, Murugan PM, Chakraborty AK. Optimizing immunization protocols to elicit broadly neutralizing antibodies. Proc Natl Acad Sci U S A 2020; 117(33): 20077-87. [DOI:10.1073/pnas.1919329117] [PMID] []
29. Bonenfant C, Dimier-Poisson I, Velge-Roussel F, Buzoni-Gatel D, Del Giudice G, Rappuoli R, Bout D. Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii. Infect Immun 2001; 69(3): 1605-12. [DOI:10.1128/IAI.69.3.1605-1612.2001] [PMID] []
30. Lee BS, Huang JS, Jayathilaka LP, Lee J, Gupta S. Antibody Production with Synthetic Peptides. Methods Mol Biol 2016; 1474: 25-47. [DOI:10.1007/978-1-4939-6352-2_2] [PMID]
31. Ait Mebarek M, Wijkhuisen A, Adel-Patient K, Lamourette P, Léonetti M, Volland H. Production of human antibodies by in vitro immunization using a fusion protein containing the transcriptional transactivator of HIV-1. J Immunol Methods 2013; 396(1-2): 96-106. [DOI:10.1016/j.jim.2013.07.015] [PMID]
32. Tamura T, Tomimatsu K, Katakura Y, Yamashita M, Matsumoto SE, Aiba Y, et al. Anti-peptide antibody production elicited by in vitro immunization of human peripheral blood mononuclear cells. Biosci Biotechnol Biochem 2007; 71(12): 2871-5. [DOI:10.1271/bbb.60460] [PMID]
33. Ho MK, Rand N, Murray J, Kato K, Rabin H. In vitro immunization of human lymphocytes. I. Production of human monoclonal antibodies against bombesin and tetanus toxoid. J Immunol 1985; 135(6): 3831-8. [DOI:10.4049/jimmunol.135.6.3831]
34. Yamashita M, Katakura Y, Shim SY, Matsumoto SE, Tamura T, Morihara K, et al. Different individual immune responses elicited by in vitro immunization. Cytotechnology 2002; 40(1-3): 161-5.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
